Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 71
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Henstridge, Christopher M. Pickett, Eleanor and Spires-Jones, Tara L. 2016. Synaptic pathology: A shared mechanism in neurological disease. Ageing Research Reviews, Vol. 28, p. 72.

    Madson, Kimberly A. and Brown, Sherrill 2016. Rivastigmine: Dementia with Lewy Bodies. Hospital Pharmacy, Vol. 51, Issue. 2, p. 129.

    Mori, Etsuro Ikeda, Manabu Nakai, Kenya Miyagishi, Hideaki Nakagawa, Masaki and Kosaka, Kenji 2016. Increased plasma donepezil concentration improves cognitive function in patients with dementia with Lewy bodies: An exploratory pharmacokinetic/pharmacodynamic analysis in a phase 3 randomized controlled trial. Journal of the Neurological Sciences, Vol. 366, p. 184.

    Mori, Etsuro Ikeda, Manabu Nagai, Reiko Matsuo, Kazutaka Nakagawa, Masaki and Kosaka, Kenji 2015. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial. Alzheimer's Research & Therapy, Vol. 7, Issue. 1,

    Saxena, Jaya Meloni, David Huang, Mou-Tuan Heck, Diane E. Laskin, Jeffrey D. Heindel, Ned D. and Young, Sherri C. 2015. Ethynylphenyl carbonates and carbamates as dual-action acetylcholinesterase inhibitors and anti-inflammatory agents. Bioorganic & Medicinal Chemistry Letters, Vol. 25, Issue. 23, p. 5609.

    Vermeiren, Yannick Van Dam, Debby Aerts, Tony Engelborghs, Sebastiaan Martin, Jean-Jacques and De Deyn, Peter P 2015. The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimer's Research & Therapy, Vol. 7, Issue. 1, p. 7.

    Han, Ding Wang, Qiong Gao, Zhongbao Chen, Tong and Wang, Zhenfu 2014. Clinical features of dementia with lewy bodies in 35 Chinese patients. Translational Neurodegeneration, Vol. 3, Issue. 1, p. 1.

    Krolak-Salmon, P. and Xie, J. 2014. Malattia a corpi di Lewy. EMC - Neurologia, Vol. 14, Issue. 4, p. 1.

    Ikeda, Manabu Mori, Etsuro Kosaka, Kenji Iseki, Eizo Hashimoto, Mamoru Matsukawa, Noriyuki Matsuo, Kazutaka and Nakagawa, Masaki 2013. Long-Term Safety and Efficacy of Donepezil in Patients with Dementia with Lewy Bodies: Results from a 52-Week, Open-Label, Multicenter Extension Study. Dementia and Geriatric Cognitive Disorders, Vol. 36, Issue. 3-4, p. 229.

    Lim, Thien Thien Chou, Kelvin L. and Fernandez, Hubert H. 2013. Handbook of Parkinson’s Disease.

    Lim, Thien Chou, Kelvin and Fernandez, Hubert 2013. Handbook of Parkinson's Disease, Fifth Edition.

    Mori, Etsuro Ikeda, Manabu and Kosaka, Kenji 2012. Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial. Annals of Neurology, Vol. 72, Issue. 1, p. 41.

    Larner, AJ 2010. Cholinesterase inhibitors: beyond Alzheimer’s disease. Expert Review of Neurotherapeutics, Vol. 10, Issue. 11, p. 1699.

    Taylor, J. -P. and McKeith, I. G. 2010. Principles and Practice of Geriatric Psychiatry.

    Haidar, Wael N. and Petersen, Ronald C. 2009. Pharmacology and Therapeutics.


    Dujardin, Kathy and Defebvre, Luc 2008. Neuropsychologie du vieillissement normal et pathologique.

    Figiel, Gary and Sadowsky, Carl 2008. A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Current Medical Research and Opinion, Vol. 24, Issue. 1, p. 157.

    Liepelt, I. Maetzler, W. Blaicher, H.-P. Gasser, T. and Berg, D. 2008. Behandlung der Demenz bei Parkinson-Syndromen. Der Nervenarzt, Vol. 79, Issue. 1, p. 36.

    Marshall, Gad A. and Cummings, Jeffrey L. 2008. Dementias.


Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial

  • Janet Grace (a1), Sarah Daniel (a1), Timothy Stevens (a2), K. K. Shankar (a3), Zuzanna Walker (a2), E. Jane Byrne (a4), Susan Butler (a4), David Wilkinson (a5), Jan Woolford (a5), Jonathon Waite (a6) and Ian G. McKeith (a1)
  • DOI:
  • Published online: 01 January 2005

Patients with dementia with lewy bodies (DLB) have progressive deficits in cognition, parkinsonism, and neuropsychiatric symptoms. Cholinesterase inhibitors have been used to ameliorate cognitive decline and neuropsychiatric symptoms in short-term trials. In this study, patients with DLB were treated with rivastigmine up to 96 weeks. Improvement from baseline was seen in cognitive function as measured by the Mini-Mental State Examination (MMSE), and neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI) over the first 24 weeks of treatment. By 96 weeks, neither the MMSE scores nor the NPI scores were significantly worse than at baseline.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *